SCHEMBL2174598

SCHEMBL2174598

CCOC(=O)C=Cc1cccc(CNC(=O)OC(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.47
DPP4 P27487 1/20 0.47
MAPT P10636 1/20 0.46
PTGS2 P35354 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
MAOB P27338 1/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2174596 1.00 TTR (0.47) TTRDPP4MAPTPTGS2MEN1
SCHEMBL1164581 0.90 NR1H4 (0.49) TTRMEN1KMT2AKDM4EALDH1A1
SCHEMBL31389315 0.90 NR1H4 (0.49) TTRMEN1KMT2AKDM4EALDH1A1
SCHEMBL3439467 0.90 NR1H4 (0.49) TTRMEN1KMT2AKDM4EALDH1A1
SCHEMBL4081996 0.89 TTR (0.45) TTRDPP4MAPTPTGS2CA12
SCHEMBL4081992 0.89 TTR (0.45) TTRDPP4MAPTPTGS2CA12
SCHEMBL8985040 0.87 MMP1 (0.51) CA12CA1CA7CA14KDM4E
SCHEMBL8985043 0.87 MMP1 (0.51) CA12CA1CA7CA14KDM4E
SCHEMBL6987937 0.86 CA12 (0.55) TTRDPP4MAPTCA12CA1
SCHEMBL30944751 0.86 CA12 (0.55) TTRDPP4MAPTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014196328-A1 HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF 日本理化学工業株式会社 (JP) 2014-12-11 WO disclosed
EP-2050446-B1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-05-07 EP disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed
EP-2050446-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF PTGER1, CYSLTR1, PTGER2 TTR 4739/4885DPP4 3510/4885MAPT 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.